SCHEMBL2184974

SCHEMBL2184974

N#Cc1ncc(-n2c3ccccc3c3c(-c4cnc5ccccc5c4)cccc32)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
EGLN2 Q96KS0 1/20 0.36
BIRC5 O15392 1/20 0.35
MTOR P42345 4/20 0.34
AKR1C3 P42330 2/20 0.34
AKR1C2 P52895 2/20 0.34
PIK3CD O00329 2/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
HSP90AA1 P07900 5/20 0.34
PIK3C2A O00443 2/20 0.33
PIK3C2B O00750 2/20 0.33
CHEK1 O14757 1/20 0.33
ABCB11 O95342 1/20 0.33
CSF1R P07333 1/20 0.33
MET P08581 1/20 0.33
PIK3R1 P27986 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185317 0.89 PIK3CA (0.40) PIK3CAPDGFRBPDGFRAEGLN2BIRC5
SCHEMBL2181737 0.86 CYP11B1 (0.42) PIK3CAPDGFRBPDGFRAMTORPIK3CD
SCHEMBL3433972 0.86 PDGFRB (0.38) PIK3CAPDGFRBPDGFRABIRC5MTOR
SCHEMBL2181700 0.85 HSP90AA1 (0.34) PDGFRBPDGFRAHSP90AA1
SCHEMBL2182164 0.80 HSP90AA1 (0.45) HSP90AA1JAK3
SCHEMBL2184680 0.80 HSP90AA1 (0.53) HSP90AA1
SCHEMBL2184084 0.80 HSP90AA1 (0.45) NPC1MAPTRAB9AHSP90AA1
SCHEMBL2183658 0.80 PDGFRB (0.38) PIK3CAPDGFRBPDGFRABIRC5MTOR
SCHEMBL2182391 0.79 PDGFRB (0.40) PIK3CAPDGFRBPDGFRABIRC5MTOR
SCHEMBL2183119 0.79 BIRC5 (0.37) PIK3CAPDGFRBPDGFRABIRC5MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309721-B2 HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof SANOFI (FR) 2012-11-13 US disclosed
US-20110166169-A1 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2011-07-07 US disclosed
EP-2265598-A2 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF Sanofi-Aventis (FR) 2010-12-29 EP disclosed
WO-2009122034-A2 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166169-A1 NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 PIK3CA 3724/4885PDGFRB 1160/4885PDGFRA 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.